期刊文献+

Role of upstream stimulatory factor 2 in diabetic nephropathy 被引量:2

Role of upstream stimulatory factor 2 in diabetic nephropathy
原文传递
导出
摘要 糖尿病的 nephropathy (DN ) 是结束阶段的最普通的原因肾的疾病(ESRD ) 。关于有类型 1 和类型 2 糖尿病的人的 20%30% 开发 DN。DN 被 glomerulosclerosis 与 glomerular 地下室膜和 mesangial 矩阵变厚描绘扩大,和 tubulointerstitial 纤维变性。多糖症和在糖尿病的 intra 肾的高血压蛋白原酶血管收缩素系统(地岬) 的激活被建议了在 DN 的致病起一个关键作用。然而,机制不是众所周知的。 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD). About 20%-30% of people with type 1 and type 2 diabetes develop DN. DN is characterized by both glomerulosclerosis with thickening of the glomerular basement membrane and mesangial matrix expansion, and tubulointerstitial fibrosis. Hyperglycemia and the activation of the intra-renal renin-angiotensin system (RAS) in diabetes have been suggested to play a critical role in the pathogenesis of DN. However, the mechanisms are not well known. Studies from our laboratory demonstrated that the transcription factor--upstream stimulatory factor 2 (USF2) is an important regulator of DN. Moreover, the renin gene is a downstream target of USF2. Importantly, USF2 transgenic (Tg) mice demonstrate a specific increase in renal renin expression and angiotensin II (AngII) levels in kidney and exhibit increased urinary albumin excretion and extracellular matrix deposition in glomeruli, supporting a role for USF2 in the development of diabetic nephropathy. In this review, we summarize our findings of the mechanisms by which diabetes regulates USF2 in kidney cells and its role in regulation of renal renin-angiotensin system and the development of diabetic nephropathy.
作者 Shuxia Wang
出处 《Frontiers in Biology》 CAS CSCD 2015年第3期221-229,共9页 生物学前沿(英文版)
  • 相关文献

参考文献112

  • 1Andersen S, Tamow L, Rossing P, Hansen B V, Parving H H (2000). Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int, 57(2): 601- 606.
  • 2Anderson S, Jung F F, Ingelfinger J R (1993). Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol, 265(4 Pt 2): F477-F486.
  • 3Andrade A Q, Casarini D E, Schor N, Boim M A (2002). Characterization of renin mRNA expression and enzyme activity in rat and mouse mesangial cells. Braz J Med Biol Res, 35(1): 17-24.
  • 4Bertoluci M C, Schmid H, Lachat J J, Coimbra T M (1996). Transforming growth factor-beta in the development of rat diabetic nephropathy. A 10-month study with insulin-treated rats. Nephron, 74(1): 189-196.
  • 5Bidder M, Shao J S, Charlton-Kachigian N, Loewy A P, Semenkovich C F, Towler D A (2002). Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein- 1 activities. J Biol Chem, 277 (46): 44485-44496.
  • 6Borch-Johnsen K, Andersen P K, Deckert T (1985). The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 28(8): 590-596.
  • 7Border W A, Noble N A (1998a). Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int, 54(4): 1390- 1391.
  • 8Border W A, Noble N A (1998b). Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension, 31(1 Pt 2): 181-188.
  • 9Border W A, Noble N A, Ketteler M (1995). TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic interven- tion. Kidney Int Suppl, 49(61): $59-$61.
  • 10Brenner B M, Cooper M E, de Zeeuw D, Keane W F, Mitch W E, Parving H H, Remuzzi G, Snapinn S M, Zhang Z, Shahinfar S, and the RENAAL Study Investigators (2001). Effects oflosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345(12): 861-869.

同被引文献10

引证文献2

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部